De Grazia S, Bonura F, Pepe A, Li Muli S, Cappa V, Collura A, Terranova D M, Urone N, Di Bernardo F, Matranga D, Giammanco G M
Dipartimento di Scienze per la Promozione della Salute e Materno Infantile "G. D'Alessandro", Università di Palermo, Italy.
Dipartimento di Scienze per la Promozione della Salute e Materno Infantile "G. D'Alessandro", Università di Palermo, Italy.
J Virol Methods. 2017 May;243:50-54. doi: 10.1016/j.jviromet.2017.01.025. Epub 2017 Jan 31.
Group A rotaviruses (RVAs) are the primary cause of acute gastroenteritis (AGE) in young children worldwide. Several commercial tests including latex agglutination, enzyme-linked assays (ELISA) and immunochromatographic tests (ICT) have been developed for the diagnosis of RVA infection. In the present study, the performance of two commercially available one-step chromatographic immunoassays, CerTest Rotavirus+Adenovirus (Biotec S.L, Zaragoza, Spain) and Vikia Rota-Adeno (bioMerieux SA, Lyon, France) were retrospectively evaluated using Real-time PCR as reference test. Re-testing by Real-time PCR of 2096 stool samples of children hospitalized with AGE previously screened by ICTs (1467 by CerTest and 629 by Vikia) allowed to calculate higher sensitivity for Vikia (94% vs 85% of CerTest) and higher specificity for CerTest (93% vs 89% of Vikia). Accordingly, higher Positive Predictive Values (87% vs 78%) and Positive Likelihood Ratios (12.32 vs 8.8) were found for CerTest and lower Negative Predictive Values (91% vs 97%) and Negative Likelihood Ratios (0.16 vs 0.06) for Vikia. However, both CerTest and Vikia showed a substantial agreement (κ=0.79) with the Real-time PCR. A correlation between false negative results by ICTs and high Cycle Threshold values of Real-time PCR, indicative of low viral load, was observed. False positive results by the two ICT assays were not related to Norovirus, Adenovirus or Astrovirus infections, therefore the risk of cross-reactions was excluded. Both CerTest and VIKIA were able to detect the wide range of RVA genotypes circulating over the study period (including G1P[8], G2P[4], G3, G4, G9 and G12P[8]). The results of the present study showed a satisfactory efficacy of the two diagnostic tests analyzed.
A组轮状病毒(RVAs)是全球幼儿急性胃肠炎(AGE)的主要病因。已经开发了几种商业检测方法,包括乳胶凝集试验、酶联免疫吸附测定(ELISA)和免疫层析试验(ICT)用于诊断RVA感染。在本研究中,以实时荧光定量聚合酶链反应(Real-time PCR)作为参考检测方法,对两种市售的一步式免疫层析检测试剂,即CerTest轮状病毒+腺病毒检测试剂(西班牙萨拉戈萨的Biotec S.L公司)和Vikia轮状病毒-腺病毒检测试剂(法国里昂的生物梅里埃公司)的性能进行了回顾性评估。对先前通过ICT检测(1467份样本采用CerTest试剂检测,629份样本采用Vikia试剂检测)筛选出的2096份因AGE住院儿童的粪便样本进行实时荧光定量聚合酶链反应重新检测,结果显示Vikia试剂的灵敏度更高(94%,而CerTest试剂为85%),CerTest试剂的特异性更高(93%,而Vikia试剂为89%)。相应地,CerTest试剂的阳性预测值更高(87%,而Vikia试剂为78%)以及阳性似然比更高(12.32,而Vikia试剂为8.8),而Vikia试剂的阴性预测值更低(91%,而CerTest试剂为97%)以及阴性似然比更低(0.16,而Vikia试剂为0.06)。然而,CerTest试剂和Vikia试剂与实时荧光定量聚合酶链反应均显示出高度一致性(κ=0.79)。观察到ICT检测的假阴性结果与实时荧光定量聚合酶链反应的高循环阈值之间存在相关性,高循环阈值表明病毒载量较低。两种ICT检测方法的假阳性结果与诺如病毒、腺病毒或星状病毒感染无关,因此排除了交叉反应的风险。CerTest试剂和VIKIA试剂均能够检测在研究期间流行的广泛RVA基因型(包括G1P[8]、G2P[4]、G3、G4、G9和G12P[8])。本研究结果表明所分析的两种诊断检测试剂具有令人满意的效能。